SAB Biotherapeutics, Inc., (SABS): Price and Financial Metrics
GET POWR RATINGS... FREE!
SABS Stock Price Chart Interactive Chart >
SABS Price/Volume Stats
|Current price||$1.98||52-week high||$12.90|
|Prev. close||$1.94||52-week low||$1.61|
|Day high||$2.00||Avg. volume||173,177|
|50-day MA||$2.37||Dividend yield||N/A|
|200-day MA||$6.61||Market Cap||85.06M|
SAB Biotherapeutics, Inc., (SABS) Company Bio
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic for the treatment of COVID-19 advancing as part of the NIH's ACTIV-2 protocol; and SAB-176, a fully-human polyclonal antibody therapeutic candidate designed to bind to type A and B viruses. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection; and SAB-181 for immune globulin (IgG) mediated diseases. It focuses on infectious diseases, such as COVID-19 and influenza, immune system disorders comprising type 1 diabetes, organ transplantation, and cancer. The company was founded in 2014 and is based in Miami Beach, Florida.
Most Popular Stories View All
SABS Latest News Stream
|Loading, please wait...|
SABS Latest Social Stream
View Full SABS Social Stream
Latest SABS News From Around the Web
Below are the latest news stories about SAB Biotherapeutics Inc that investors may wish to consider to help them evaluate SABS as an investment opportunity.
Every investor in SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) should be aware of the most powerful shareholder groups...
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
SAB-185 is being evaluated in Phase 3 NIH-Sponsored ACTIV-2 COVID trial of high-risk patients following positive DSMB review of interim Phase 2 safety and efficacy data in September More than 700 patients have been enrolled in the Phase 3 trial, exceeding 50% enrollment SAB-185’s targeted, highly potent and fully-human polyclonal antibodies have demonstrated neutralization of SARS-CoV-2 viral variants, including Delta and Omicron SAB-185 was safe and well-tolerated at both doses tested in Phase
Investment company First PREMIER Bank (Current Portfolio) buys SAB Biotherapeutics Inc, Amplify Transformational Data Sharing ETF, 3M Co, Global X Lithium & Battery Tech ETF, BHP Group, sells , iShares 0-5 Year TIPS Bond ETF, iShares Core 1-5 Year USD Bond ETF, Vanguard Short-Term Bond ETF, General Electric Co during the 3-months ended 2021Q4, according to the most recent filings of the investment company, First PREMIER Bank.
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that Eddie J. Sullivan, PhD, co-founder, president, and CEO, will present at the H.C. Wainwright BioConnect Virtual Conference occurring January 10-13, 2022. The presentation will be availa
SIOUX FALLS, S.D., Dec. 20, 2021 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, effective prior to market open on Monday, December 20, 2021. The NASDAQ Biotechnology Index is designed to track the perf
SABS Price Returns